Build NIH Ophthalmology Startup Directory via Public Grant Scraping
- Organization
- NIH RePORTER database (unstructured ophthalmology grant data)
- Sector
- Ophthalmology-focused investors, pharma scouts, and industry analysts
- Location
- Location unspecified
Source Reference
Executive Context
NIH awarded $311,049 Phase I STTR funding to OUTFLOWGEN LLC for a first-in-class CRISPR glaucoma therapy, creating a predictable commercial gap where scientific validation exists but commercialization infrastructure is absent. The structural asymmetry is between NIH's ability to fund early science and small biotechs' inability to navigate the regulatory and capital requirements for clinical development.
Catalyst / Timing
NIH's ophthalmology funding is scattered across hundreds of grants with no centralized directory. Investors and pharma scouts waste hours manually searching RePORTER instead of having a curated, filterable list of commercial opportunities.
Projected Yield
$1,000-2,000 ARR from 10-20 premium subscribers at $99/year
Structural Friction
• Vulnerability: NIH's ophthalmology funding is scattered across hundreds of grants with no centralized directory. Investors and pharma scouts waste hours manually searching RePORTER instead of having a curated, filterable list of commercial opportunities. • Capital yield: $1,000-2,000 ARR from 10-20 premium subscribers at $99/year • Resource capture: Proprietary email list of ophthalmology investors and scouts • Influence capture: Authority position as the go-to source for NIH ophthalmology deal flow • Required vectors: Vector: Data Scraping, Vector: Web Development
Required Capabilities
Vector: Data Scraping
Primary executor: Phase 1: NIH Ophthalmology Portfolio Scrape: Scrape NIH RePORTER for all R41/R42 (STTR) grants with keywords: 'glaucoma'
Vector: Web Development
Supporting vector for: Build NIH Ophthalmology Startup Directory via Public Grant Scraping
Execution Protocol
Execution Protocol Locked
A one-time payment of $49 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.